loading page

Exploration of severe Covid-19 associated risk factor in China: meta-analysis of current evidence
  • +2
  • Yun-Jing Zhang,
  • Xi-Feng Sun,
  • Bing Xie,
  • Wen-Juan Feng,
  • Shi-liang Han
Yun-Jing Zhang
Zibo Central Hospital
Author Profile
Xi-Feng Sun
Zibo Central Hospital
Author Profile
Bing Xie
Zibo Central Hospital
Author Profile
Wen-Juan Feng
Jinan Central Hospital Affiliated to Shandong University
Author Profile
Shi-liang Han
Author Profile

Abstract

Methods: We systemically and comprehensively retrieved the eligible study evaluating clinical difference between severe versus non-severe Covid-19. Main effect sizes were demography characteristics, comorbidities, signs and symptoms, laboratory findings as well as radiological features in chest CT. Results: 14 studies with a total of 2,566 individuals (771 in Severe group and 1,795 in Non-severe group) were eligible for this meta-analysis. It was demonstrated that older and male person was more susceptible to severe Covid-19. Patients with underlying comorbidity, such as hypertension, diabetes, heart disease and COPD were associated with significantly increased susceptibility of severe Covid-19. Patients with dyspnea were more likely to be severe illness. Depressed total lymphocytes were observed in this article. Meanwhile, although reticulation (30.8%), intrathoracic lymph node enlargement (56.4%) and pleural effusions (30.8%) were relatively rarely seen, meta-analysis revealed that patients with these presentations in chest CT were associated with increased risks of severe Covid-19. Conclusions: There are significant differences in clinical characteristic between the severe and non-severe Covid-19 patients. Many factors are related to the severity of the disease, which can help clinicians to differentiate severe patient from non-severe patient.

Peer review status:IN REVISION

17 Apr 2020Submitted to International Journal of Clinical Practice
20 Apr 2020Submission Checks Completed
20 Apr 2020Assigned to Editor
03 May 2020Reviewer(s) Assigned
22 Sep 2020Review(s) Completed, Editorial Evaluation Pending
13 Nov 20201st Revision Received
15 Nov 2020Submission Checks Completed
15 Nov 2020Assigned to Editor
15 Nov 2020Reviewer(s) Assigned
18 Feb 2021Review(s) Completed, Editorial Evaluation Pending
19 Apr 20212nd Revision Received
19 Apr 2021Assigned to Editor
19 Apr 2021Submission Checks Completed